The Marked Chart Wire · Business
Regeneron
Regeneron revenue growth driven by Dupixent profit share despite Eylea decline
Regeneron revenue continues to grow at a solid pace even as sales of its Eylea drug fall. The company's profit share from Dupixent is emerging as a key driver of its financial performance.
